Search research articles
Contact Us
Filters
Showing results (81-90 of 110) with videos related to
Page
of 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
A Bernard-Tessier, C Baldini, Patricia Martin, et al.
International Journal of Cardiology
|
April 17, 2016
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials
Antoine Hollebecque, Emilie Lanoy, Frederic Troallen, et al.
Nature Communications
|
September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics
|
February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
BMC Cancer
|
March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Janice M Mehnert, Andrea Varga, Marcia S Brose, et al.
European Heart Journal. Cardiovascular Imaging
|
September 28, 2022
Subclinical leaflet thrombosis after transcatheter aortic valve implantation is associated with silent brain injury on brain magnetic resonance imaging
Astrid Apor, Andrea Bartykowszki, Bálint Szilveszter, et al.
Clinical Kidney Journal
|
February 13, 2019
Renal toxicities associated with pembrolizumab
Hassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 22, 2017
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
Frédéric Bigot, Eduardo Castanon, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2018
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 110) with videos related to
Sort By:
Page
of 11
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2018
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
A Bernard-Tessier, C Baldini, Patricia Martin, et al.
International Journal of Cardiology
|
April 17, 2016
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials
Antoine Hollebecque, Emilie Lanoy, Frederic Troallen, et al.
Nature Communications
|
September 1, 2016
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung, Joon Sang Lee, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Molecular Cancer Therapeutics
|
February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Matteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
BMC Cancer
|
March 6, 2019
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer
Janice M Mehnert, Andrea Varga, Marcia S Brose, et al.
European Heart Journal. Cardiovascular Imaging
|
September 28, 2022
Subclinical leaflet thrombosis after transcatheter aortic valve implantation is associated with silent brain injury on brain magnetic resonance imaging
Astrid Apor, Andrea Bartykowszki, Bálint Szilveszter, et al.
Clinical Kidney Journal
|
February 13, 2019
Renal toxicities associated with pembrolizumab
Hassan Izzedine, Alexis Mathian, Stephane Champiat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 22, 2017
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
Frédéric Bigot, Eduardo Castanon, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2018
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Léa Gauci, Emilie Lanoy, Stéphane Champiat, et al.
Page
of 11